Table 3.

Relation of statin use to 5-year incidence or progression of age-related macular degeneration (AMD) in Beaver Dam Eye Study, 1998-00 to 2003-05

		Unadjusted			Age and gender adjusted			Multivariate adjusted *
Outcome	History of Statin use	N	%	P	OR	95% CI	P	OR	95% CI	P
Incidence of Early AMD	No	1347	5.9	0.53	1.00			1.00
	Yes	339	6.8		1.11	(0.68, 1.82)	0.67	1.16	(0.71, 1.91)	0.55
Incidence of Late AMD	No	1638	1.8	0.43	1.00			1.00
	Yes	429	2.3		1.32	(0.63, 2.78)	0.47	1.27	(0.60, 2.69)	0.53
Incidence of Exudative AMD	No	1653	1.0	0.30	1.00			1.00
	Yes	434	1.6		1.56	(0.63, 3.86)	0.33	1.51	(0.61, 3.77)	0.37
Incidence of Pure Geographic Atrophy	No	1624	0.9	1.00	1.00			1.00
	Yes	422	0.7		0.89	(0.25, 3.20)	0.86	0.84	(0.23, 3.06)	0.79
Progression of AMD	No	1650	6.5	0.45	1.00			1.00
	Yes	427	7.5		1.13	(0.74, 1.74)	0.56	1.16	(0.75, 1.78)	0.51
Incidence of large drusen (≥ 125 μm)	No	1349	9.2	0.35	1.00			1.00
	Yes	364	7.4		0.74	(0.47, 1.16)	0.19	0.80	(0.51, 1.25)	0.32
Incidence of soft indistinct drusen	No	1439	7.2	1.00	1.00			1.00
	Yes	370	7.0		0.95	(0.60, 1.51)	0.84	0.93	(0.59, 1.49)	0.78
Incidence of pigmentary abnormalities	No	1424	3.3	0.21	1.00			1.00
	Yes	365	4.7		1.40	(0.78, 2.51)	0.25	1.49	(0.83, 2.69)	0.18

OR=odds ratio, CI=confidence interval

^*Adjusted for age (categorically), sex, smoking history and vitamin use